Sleep Disorders Clinical Trial
— SleepTx-1Official title:
Daily Light Intervention in Renal Transplant Recipients Having a Sleep-Wake Dysregulation
Verified date | January 2014 |
Source | University of Basel |
Contact | n/a |
Is FDA regulated | No |
Health authority | Switzerland: Ethikkommission |
Study type | Interventional |
Sleep-wake dysregulation is a disturbance in the roughly 24-hour cycle of the circadian
rhythm. Well known disorders presenting a sleep-wake dysregulation are seasonal affective
disorder, jet lag and shift work. These people experience a serious mood change when the
seasons change. When the day-night rhythm is desynchronized, they have sleep disturbances,
little energy, and often feel depressed. An established intervention to treat this disorder
is bright light therapy. Light therapy is used for affective disorders for shift workers,
jet lag symptomatology and for advancing or delaying desynchronized rhythms.Two proxy
measures for sleep-wake dysregulation are sleep quality and daytime sleepiness. It is known
from cross sectional studies that renal transplant (RTx) recipients have a prevalence
between 30% to 62% of poor sleep quality measured by self report; a prevalence of impaired
daytime functioning of 34% 12 and a prevalence of depressive symptomatology of 20% to 22%.
Sleep-wake dysregulation in other chronically ill population are a risk factor for morbidity
and mortality.
RTx nurses in the follow-up care are in the frontline for recipient's symptoms respectively
problems. The psychosocial variables that should be addressed, having an association with
morbidity and mortality are sleep, daytime functioning, adherence to immunosuppressive
medication, exercise, smoking and depressive symptomatology.
In the following research project we will address the following gaps: the fact that nature
of sleep disturbances in RTx recipients has never been assessed, that there is no prevalence
available on sleep-wake dysregulation and that there is no data on bright light therapy
intervention in RTx recipients.
Hypothesis: Renal transplant recipients having a sleep wake disregulation will have an
improved sleep quality and less daytime sleepiness after 21 days of light therapy.
Status | Completed |
Enrollment | 30 |
Est. completion date | July 2013 |
Est. primary completion date | June 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - For phase 1: all renal transplant recipients transplanted at the University Hospital Basel, Bern and Zurich, speaking German and having an actual address on the follow-up list of the ambulatory center list. - Renal transplant recipients who have poor Sleep quality and /or daytime sleepiness (phase 1: Cross sectional survey study) and had a Sleep assessment (phase 2: Cross sectional diagnostic interview study) - Renal transplant recipients who participated in Phase 1 and 2 that were diagnosed with sleep wake dysregulation - Renal transplant recipients with signed written informed consent. Exclusion Criteria: - RTx recipients, who participated in phase 2, will be excluded in the study if - they were diagnosed with sleep disorders as parasomnia, breathing disorders or movement disorders. - they were diagnosed with alcohol or substance abuse - they are blind or suffer from a severe vision impairment (cataract), which possibly limits the effect of the light intervention and patients taking photosensitive medications |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Basel | University Hospital Inselspital, Berne, University Hospital, Basel, Switzerland, University Hospital, Zürich |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Bedtime | The mean "bedtime" assessed by actimetry of each 3 week period (day 21, 42, 63 ) was used as outcome to be compared with the control group. Bedtime is expressed in time (hours and minutes) |
Mean Bedtimes over 21 days for each period | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02188498 -
Electrocardiography Data Analysis in Sleep Disorders
|
||
Completed |
NCT00990106 -
Augmentation Trial of Prazosin for Post-Traumatic Stress Disorder (PTSD)
|
N/A | |
Completed |
NCT00942253 -
Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS)
|
Phase 2 | |
Completed |
NCT00163670 -
The Impact of Sleep Disorders on Motor Vehicle Accidents
|
N/A | |
Completed |
NCT00203827 -
Pediatric Sleep Questionnaire: Use for Collection of Clinical Data
|
N/A | |
Completed |
NCT00256685 -
Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause
|
Phase 3 | |
Completed |
NCT00174174 -
Provigil (Modafinil) Study by Taiwan Biotech Co.
|
N/A | |
Terminated |
NCT00750919 -
Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)
|
Phase 3 | |
Completed |
NCT02939586 -
The Effect of Haemodialysis in Sleep Apnoea
|
N/A | |
Completed |
NCT03075241 -
Z-Drugs for Sleep Disorders in Alzheimer's Disease
|
Phase 3 | |
Completed |
NCT02585609 -
Sleep Quality in Patients With Advanced Cancer
|
N/A | |
Completed |
NCT03055156 -
Effect of High Rebound Mattress Toppers on Sleep and Sleep-Related Symptoms
|
N/A | |
Completed |
NCT01906866 -
Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities
|
Phase 3 | |
Completed |
NCT01929447 -
Evaluation of WP200 With the Unified Probe (WP200U)
|
N/A | |
Completed |
NCT02156128 -
Subjective Memory Complaints, Objective Memory Performance and Cognitive Training
|
N/A | |
Completed |
NCT01528462 -
Sleep Disorders Managed and Assessed Rapidly in Transient Ischemic Attack (TIA) and In Early Stroke
|
||
Completed |
NCT01220401 -
Efficacy of a Brief Nightmare Treatment for Veterans
|
N/A | |
Not yet recruiting |
NCT00749814 -
Sleep Disturbances in Hospitalized Children
|
Phase 4 | |
Completed |
NCT00518986 -
Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression
|
Phase 4 | |
Completed |
NCT00397930 -
Yoga in Treating Sleep Disturbance in Cancer Survivors
|
Phase 2 |